PHG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term focus, and available capital, Koninklijke Philips NV (PHG) is not a strong buy at this time. The stock shows mixed technical signals, weak financial performance, and limited positive catalysts. It is advisable to hold off on investing in PHG until clearer growth signals or stronger positive catalysts emerge.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 34.506, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the pre-market price is down 1.56%, and the stock is near its support level of 27.635, suggesting limited immediate upside potential.
Recent FDA 510(k) clearances for innovative imaging and cancer treatment systems (Rembra CT, Rembra RT, Areta RT, and Spectral CT Verida) highlight Philips' advancements in healthcare technology.
Hedge funds are aggressively selling, with a 30126.47% increase in selling activity last quarter. Analysts have lowered price targets, and the stock has been removed from Goldman's European Conviction List. Financial performance shows a significant YoY drop in net income (-228.70%) and EPS (-226.32%).
In Q4 2025, revenue increased by 10.32% YoY, and gross margin improved by 15.31%. However, net income dropped by -228.70%, and EPS fell by -226.32%, indicating profitability challenges.
Analysts are neutral to bearish. Deutsche Bank recently lowered the price target to EUR 25 from EUR 29 with a Hold rating. Morgan Stanley raised the target slightly to EUR 26 but maintained an Equal Weight rating. Goldman Sachs removed PHG from its European Conviction List.
